Montreal, Thursday, January 7, 2010 - Serge Beausoleil, president of Viropro Inc. is pleased to appoint Scott M. Brown, Ph. D. as Chief Scientific Officer and member of the Viropro Board, effective immediately.

Dr. Brown received his Ph.D. in microbiology from UCLA.  After postdoctoral studies in molecular biology at the University of Colorado, Boulder, he began his career in the biotechnology industry. 

Dr. Brown has over 25 years of industrial experience in cloning and expressing heterologous genes in microbial and non-microbial systems as well as protein purification from native and recombinant sources. He has used cell culture systems ranging in size from 5 to 100 L for insect and mammalian cells and up to 1600 L for yeast and bacteria.  Dr. Brown has extensive experience scaling protein purification schemes using FPLC, BioPilot and BioProcess systems with columns up to 45 cm in diameter.

Dr. Brown has acted as liaison and biologics technology transfer supervisor between BPD clients and their contract research and manufacturing organizations.  He has been the recipient of two SBIR grants and is the author of several US and European patents in the broad area of drug development and diagnostic biotechnology. He has also been an invited speaker at both domestic and international meetings.

Since 1996, Dr. Brown has been President and CSO of Biologics Process Development Inc. where he will remain at the helm of the Company.

Serge Beausoleil comments: “Scott is a terrific addition to our team; he has acute knowledge of genetics and protein purification, and of the biotech industry as a whole. Our team is growing strong and this by itself is good news.”

The appointment of Dr. Brown comes as part of the reorganization of business between Intas Biopharmaceuticals Ltd, Biologics Process Development Inc. and Viropro.

Viropro Inc. conducts operations through its subsidiary Viropro International Inc., specializes in the transfer of its technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis or multiple sclerosis. The company’s principal objective is to provide manufacturing process technology transfers to pharmaceutical companies in emerging markets with unmet medical needs such as in South America, Asia and Africa. (www.viropro.com)

About Biological Process Development, Inc.:

BPD, located near San Diego in Poway, CA, has been providing contract laboratory services to the biotechnology and biopharmaceutical industries for more than a decade. BPD services include molecular biology, cell culture, fermentation, protein purification, frozen storage, contract manufacturing, process scale-up and consulting. BPD has an impressive list of clients that range from university laboratories to well-known biotechnology and biopharmaceutical companies. (www.biologicspd.com)

About Intas Biopharmaceuticals Limited:

Intas Biopharmaceuticals Limited is a fully integrated biopharmaceutical company based out of Ahmedabad, Gujarat, India. Since launch of biotechnology operations in May 2000, Research & Development (R&D) and Manufacturing of Biopharmaceutical products with a special focus on Oncology (Cancer) are the major thrust areas for the company. Intas Biopharmaceuticals is India's first and only biopharmaceutical company to receive European Union -Good Manufacturing Practice (EU-GMP) certification for its manufacturing facility. (www.intasbiopharma.co.in)

Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.

For more information on Viropro Inc., please visit our website onwww.viropro.com